Vistagen Appoints Nick Tressler as Chief Financial Officer, Strengthening Leadership Team Amid Growth and Clinical Milestones Vistagen Therapeutics, Inc. a late clinical-stage biopharmaceutical company focused on pioneering neuroscience innovations through nose-to-brain neurocircuitry, today announced the appointment of Nick Tressler as…
Omeros Corporation Announces Completion of Asset Purchase and License Agreement with Novo Nordisk for Zaltenibart a Late-Stage MASP-3 Inhibitor Omeros Corporation today announced the successful closing of its previously disclosed asset purchase and licensing transaction with Novo Nordisk, involving the…
Arrowhead Pharmaceuticals Reports Fiscal Year 2025 Financial Results and Highlights Major Regulatory and Clinical Milestones Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its financial results for the fiscal year ending September 30, 2025, alongside a comprehensive review of recent scientific,…
Allurion Unveils Initial Results on Program + Tirzepatide Combo Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR)—a global leader in innovative, non-surgical weight-loss technology—today announced encouraging initial results from a case series evaluating the impact of combining the Allurion…
Pathway to Cures Invests in SeraGene Therapeutics The fifth paragraph of the original release dated November 19, 2025, should read: Pathway to Cures joins Hextwo Capital as early investors in SeraGene Therapeutics.The fully updated and expanded release appears below. PATHWAY…
AstraZeneca Announces $2 Billion Expansion to Strengthen Maryland Manufacturing, Advance Innovation, and Support 2,600 Jobs AstraZeneca today unveiled a major strategic investment plan totaling $2 billion to expand its long-standing manufacturing presence in Maryland, further solidifying the state’s role as…
Parabilis Medicines Announces Compelling Preliminary Clinical Results for FOG-001 in Adamantinomatous Craniopharyngioma at SNO 2025 Parabilis Medicines, a clinical-stage biopharmaceutical company dedicated to developing transformative therapies for patients with cancer, announced new preliminary clinical data highlighting the therapeutic promise of…
Quanterix Announces Comprehensive Board and Leadership Enhancements to Accelerate Its Next Phase of Strategic Growth Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a global leader in ultrasensitive biomarker detection and a pioneer in translating biomarker discoveries into impactful diagnostic…
BeOne Medicines Announces Positive Phase 3 HERIZON-GEA-01 Results Supporting ZIIHERA®-Based Regimens as Transformative First-Line Options for HER2-Positive Gastroesophageal Adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company committed to developing innovative therapies for hard-to-treat cancers,…
Avenzo Therapeutics Announces Appointment of Scott Lipman as Chief Financial Officer, Strengthening Executive Leadership to Advance Next-Generation Oncology Pipeline Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced a significant expansion of its leadership team…
Lifordi Immunotherapeutics Announces Major Strategic Investment Led by Sanofi Ventures, Strengthening Support from Existing Investors and Advancing a Transformative ADC Platform for Autoimmune and Inflammatory Diseases Lifordi Immunotherapeutics, Inc., a rapidly advancing clinical-stage biotechnology company pioneering the application of antibody-drug…
Enanta Pharmaceuticals Reports Fiscal Fourth Quarter and Full-Year 2025 Financial Results and Highlights Major Clinical Advancements Across Virology and Immunology Programs Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company developing differentiated small-molecule medicines for viral infections and immunological disorders,…